Helicobacter pylori-derived neutrophil-activating protein increases the lifespan of monocytes and neutrophils

Cappon, A.; C, Babolin; Segat, Daniela; Cancian, Laila; Amedei, Amedeo; Calzetti, Federica; Cassatella, Marco A.; D’Elios, Mario Milco; Bernard, Marina de

doi:10.1111/j.1462-5822.2010.01431.x

Cited by 18 publications

(8 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For such a purpose, slan + monocytes and, for comparison, autologous CD14 + monocytes, were cultured for up to 8 d in vitro, either in control medium or in supernatants derived from primary colon adenocarcinoma (SW480) and matched lymph node metastatic (SW620) cell lines or from a breast carcinoma cell line (MCF7). By doing so, first of all we noticed that, consistent with previous data, the viability of both slan + and CD14 + monocytes dramatically decreased within 1 d of incubation in control medium, reaching minimal values at, respectively, d 4 and 8 (Fig. A and D).…”

Section: Resultssupporting

confidence: 89%

Potential contribution of tumor-associated slan+ cells as anti-CSF-1R targets in human carcinoma

Lonardi

Licini

Micheletti

et al. 2017

Journal of Leukocyte Biology

Self Cite

View full text Add to dashboard Cite

The precise identification of the types and respective roles of the tumor-associated myeloid cells, which include tumor-associated Mϕs (TAMs), neutrophils, dendritic cells, and myeloid-derived suppressor cells, is under intensive investigation. Although tumor-associated myeloid cells may contribute to tumor cell eradication by virtue of their effector functions, they are retained to fulfill predominantly protumorigenic roles. It follows that depletion of tumor-associated myeloid cells represents one of the currently pursued therapeutic options in advanced malignancies. In that regard, RG7155/emactuzumab, a specific anti-CSF-1R humanized Ab, has been reported recently to deplete CSF-1R TAMs, in association with objective clinical responses in patients with advanced cancer. Because RG7155/emactuzumab has also been shown to deplete blood non-classic CD14 CD16 monocytes, which in large part include the CD16 slan monocytes, we asked whether RG7155/emactuzumab could target tumor-associated slan cells. In this study, we confirmed that slan cells localize only to metastatic tumor-draining lymph nodes, not to primary tumors or distant metastases in patients with different types of carcinoma. Notably, by cell scoring on serial sections, we found that slan cells represent a minor fraction of the total CSF-1R cell pool, suggesting that slan cells potentially represent minor targets of anti-CSF-1R therapy. Therefore, a protumorigenic role for slan cells, such as that of CSF-1R TAMs, based on our current data, remains questionable.

show abstract

Section: Resultssupporting

confidence: 89%

Potential contribution of tumor-associated slan+ cells as anti-CSF-1R targets in human carcinoma

Lonardi

Licini

Micheletti

et al. 2017

Journal of Leukocyte Biology

Self Cite

View full text Add to dashboard Cite

show abstract

“…While NapA mediates damage to DNA by stimulating neutrophil to produce reactive oxide species, it protects DNA by combating oxidative stress with its ferroxidase center 15 , 16 . NapA neither has toxic effect on monocytes and neutrophils nor reduces their viability or lifespan, although it can enhance production of nitric oxide 17 , 18 . These data warrant approaches on application of NapA as a vaccine candidate or immunotherapy agent 17 .…”

Section: Introductionmentioning

confidence: 99%

Production and delivery of Helicobacter pylori NapA in Lactococcus lactis and its protective efficacy and immune modulatory activity

Peng

Zhang

Wang

et al. 2018

Sci Rep

View full text Add to dashboard Cite

Helicobacter pylori neutrophil-activating protein A subunit (NapA) has been identified as a virulence factor, a protective antigen and a potent immunomodulator. NapA shows unique application potentials for anti-H. pylori vaccines and treatment strategies of certain allergic diseases and carcinomas. However, appropriate production and utilization modes of NapA still remain uncertain to date. This work has established a novel efficient production and utilization mode of NapA by using L. lactis as an expression host and delivery vector, and demonstrated immune protective efficacy and immune modulatory activity of the engineered L. lactis by oral vaccination of mice. It was observed for the first time that H. pylori NapA promotes both polarized Th17 and Th1 responses, which may greatly affect the clinical application of NapA. This report offers a promising anti-H. pylori oral vaccine candidate and a potent mucosal immune modulatory agent. Meanwhile, it uncovers a way to produce and deliver the oral vaccine and immunomodulator by fermentation of food like milk, which might have striking effects on control of H. pylori infection, gastrointestinal cancers, and Th2 bias allergic diseases, including many food allergies.

show abstract

“…Inflammation in response to H. pylori infection may not only be induced by recruitment of leukocytes, but, alternatively, the induction of IL‐1β by H. pylori neutrophil‐activating protein (HP‐NAP) may increase survival of inflammatory monocytes, and in turn neutrophils extending the local life time of these cells, as shown by Cappon et al. [23]. Several studies have shed more light to the many facets of IL‐1β in this infection, such as the loosening of tight junctions by disrupting claudin‐4 [24], and the involvement of sonic hedge hog signaling in IL‐1‐dependent reduction in gastric acid output [25].…”

Section: Inflammatory and Innate Immune Response To Infectionmentioning

confidence: 99%

“…Wong et al [22] recent characterization of macrophage migration inhibitory factor (MIF) expression in mice infected with H. pylori revealed that a negligible inflammatory response in H. pylori-infected MIF-deficient mice correlated with a substantially reduced inflammatory T-cell response, characterized by lower IFN-c and TNF-a production. Inflammation in response to H. pylori infection may not only be induced by recruitment of leukocytes, but, alternatively, the induction of IL-1b by H. pylori neutrophil-activating protein (HP-NAP) may increase survival of inflammatory monocytes, and in turn neutrophils extending the local life time of these cells, as shown by Cappon et al [23]. Several studies have shed more light to the many facets of IL-1b in this infection, such as the loosening of tight junctions by disrupting claudin-4 [24], and the involvement of sonic hedge hog signaling in IL-1dependent reduction in gastric acid output [25].…”

Section: Innate Inflammatory Mediatorsmentioning

confidence: 99%

Inflammation, Immunity, and Vaccines for Helicobacter

2010

View full text Add to dashboard Cite

Helicobacter pylori represents the major etiologic agent of gastritis, gastric, and duodenal ulcer disease and can cause gastric cancer and mucosa‐associated lymphoid tissue B‐cell lymphoma. It is clear that the consequences of infection reflect diverse outcomes of the interaction of bacteria and host immune system. The hope is that by deciphering the deterministic rules – if any – of this interplay, we will eventually be able to predict, treat, and ultimately prevent disease. Over the past year, research on the immunology of this infection started to probe the role of small noncoding RNAs, a novel class of immune response regulators. Furthermore, we learned new details on how infection is detected by innate pattern recognition receptors. Induction of effective cell‐mediated immunity will be key for the development of a vaccine, and new work published analyzed the relevance and contribution of CD4 T helper cell subsets to the immune reaction. Th17 cells, which are also induced during natural infection, were shown to be particularly important for vaccination. Cost‐efficiency of vaccination was re‐assessed and confirmed. Thus, induction and shaping of the effector roles of such protective Th populations will be a target of the newly described vaccine antigens, formulations, and modes of application that we also review here.

show abstract

Helicobacter pylori-derived neutrophil-activating protein increases the lifespan of monocytes and neutrophils

Cited by 18 publications

References 34 publications

Potential contribution of tumor-associated slan+ cells as anti-CSF-1R targets in human carcinoma

Potential contribution of tumor-associated slan+ cells as anti-CSF-1R targets in human carcinoma

Production and delivery of Helicobacter pylori NapA in Lactococcus lactis and its protective efficacy and immune modulatory activity

Inflammation, Immunity, and Vaccines for Helicobacter

Contact Info

Product

Resources

About